Hatvet Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 5.00 M
as on 16-11-2024
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.09 Cr
as on 16-11-2024
- Revenue 27.41%
(FY 2023)
- Profit -7.89%
(FY 2023)
- Ebitda 122.42%
(FY 2023)
- Net Worth 353.70%
(FY 2023)
- Total Assets 33.80%
(FY 2023)
About Hatvet Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company has closed loans amounting to ₹2.09 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rajnish Tyagi and Rashmi Tyagi serve as directors at the Company.
- CIN/LLPIN
U51397UP2019PTC112978
- Company No.
112978
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jan 2019
- Date of AGM
29 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Meerut, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Hatvet Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajnish Tyagi  | Managing Director | 29-Jan-2019 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rashmi Tyagi | Director | 29-Jan-2019 | Current |
Financial Performance of Hatvet Pharma.
Hatvet Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 27.41% increase. The company also saw a slight decrease in profitability, with a 7.89% decrease in profit. The company's net worth Soared by an impressive increase of 353.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hatvet Pharma?
In 2023, Hatvet Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hatvet Pet Passion Private LimitedActive 3 years 5 monthsRajnish Tyagi and Rashmi Tyagi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 13 Dec 2022 | ₹1.20 Cr | Satisfied |
State Bank Of India Creation Date: 13 Mar 2020 | ₹8.90 M | Satisfied |
How Many Employees Work at Hatvet Pharma?
Unlock and access historical data on people associated with Hatvet Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hatvet Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hatvet Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
